Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | TYR | P14679 | 1/20 | 0.66 |
| ▸ | CA7 | P43166 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.66 |
| ▸ | TTR | P02766 | 1/20 | 0.65 |
| ▸ | APP | P05067 | 1/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | P4HB | P07237 | 1/20 | 0.60 |
| ▸ | MMP1 | P03956 | 9/20 | 0.59 |
| ▸ | MMP2 | P08253 | 9/20 | 0.59 |
| ▸ | MMP9 | P14780 | 9/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30676338 | 1.00 | CA12 (0.66) | CA12CA1CA2TYRCA7 | |
| SCHEMBL3065424 | 1.00 | CA12 (0.66) | CA12CA1CA2TYRCA7 | |
| SCHEMBL69618 | 0.91 | TTR (0.66) | CA12CA1CA2TYRCA7 | |
| SCHEMBL14800037 | 0.85 | AKR1B10 (0.59) | P4HBMMP1MMP2MMP9AKR1B10 | |
| SCHEMBL2614742 | 0.84 | TTR (0.58) | CA12CA1CA2TYRCA7 | |
| SCHEMBL2280674 | 0.84 | TTR (0.58) | CA12CA1CA2TYRCA7 | |
| SCHEMBL13256239 | 0.84 | TTR (0.58) | CA12CA1CA2TYRCA7 | |
| SCHEMBL4084338 | 0.84 | TTR (0.58) | CA12CA1CA2TYRCA7 | |
| SCHEMBL2280675 | 0.84 | TTR (0.58) | CA12CA1CA2TYRCA7 | |
| SCHEMBL31380287 | 0.84 | TTR (0.58) | CA12CA1CA2TYRCA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111073469-A | Anti-yellowing powder coating for architectural decoration | 王磊 | 2020-04-28 | — | — | CN | claimed |
| WO-2024242120-A1 | PATTERN FORMING METHOD AND PROCESSING LIQUID FOR METAL COMPOUND-CONTAINING FILM | 東京応化工業株式会社 | 2024-11-28 | — | — | WO | disclosed |
| EP-4438596-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS HDAC AND DHFR DUAL-TARGETING INHIBITORS AND USE THEREOF IN PREVENTING AND TREATING MALARIA | Université de Lille (FR) | 2024-10-02 | — | — | EP | disclosed |
| US-11725007-B2 | Meta tyrosine derivatives as rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-08-15 | — | — | US | disclosed |
| CN-109678923-B | Tripterine (iso) ferulic acid ester derivative and preparation method and application thereof | 中国药科大学 | 2021-04-27 | — | — | CN | disclosed |
| CN-111073469-A | Anti-yellowing powder coating for architectural decoration | 王磊 | 2020-04-28 | — | — | CN | disclosed |
| US-9181186-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150045378-A1 | AROMATIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-12 | — | — | US | disclosed |
| EP-2816032-A1 | AROMATIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-12-24 | — | — | EP | disclosed |
| US-8304017-B2 | Method of producing a patterned birefringent product | FUJIFILM CORPORATION (JP) | 2012-11-06 | — | — | US | disclosed |
| EP-0889877-A1 | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-13 | — | — | EP | disclosed |
| US-5852210-A | Cinnamic acid derivatives | G. D. SEARLE & CO. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0882029-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | Merck & Co., Inc. (US) | 1998-12-09 | — | — | EP | disclosed |
| US-5773646-A | INTEGRIN INHIBITORS | G. D. SEARLE & CO. (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1997048676-A1 | TRIPHENYLALKYL ANTIMICROBIAL AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997036860-A1 | CINNAMIC ACID DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997036862-A1 | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
| WO-1997028137-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| US-5643950-A | INHIBITORS OF A BACTERIAL HISTIDINE PROTEIN KINASE | ORTHO PHARMACEUTICAL CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| US-4117234-A | DERIVATIVES OF 2-(6-PHENYLHEX-3-ENYL)-CYCLOPENT-2-EN-1-OL | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045378-A1 | AROMATIC RING COMPOUND | GPR119, GPR27, GPR4 | CA12 4521/4885CA1 4692/4885CA2 2214/4885 |
| US-11725007-B2 | Meta tyrosine derivatives as rho-kinase inhibitors | ROCK1, ROCK2, RHOA | CA12 4109/4885CA1 4180/4885CA2 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.